Troels Holz Borch

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 15

Top Venues

Journal for immunotherapy of cancer

Oncoimmunology

Cancers

Muscle & nerve

National Center for Cancer Immune Therapy

This page only lists publications with an associated author ORCID identifier.

Affiliation History

National Center for Cancer Immune Therapy Aug 01 2013

Denmark

MD, PhD :: Department of Oncology

Publications

Víctor Albarrán Fernández, Pablo Ballestín Martínez, Joachim Stoltenborg Granhøj, Troels Holz Borch, Marco Donia, Inge Marie Svane
Biomarkers for response to TIL therapy: a comprehensive review. Journal for immunotherapy of cancer 12 (3) (2024)
Víctor Albarrán Fernández, Pablo Ballestín Martínez, Joachim Stoltenborg Granhøj, Troels Holz Borch, Marco Donia, Inge Marie Svane
Biomarkers for response to TIL therapy: a comprehensive review. Journal for immunotherapy of cancer 12 (3) (2024)
Renske M T Ten Ham, Maartje W Rohaan, Inge Jedema, Rob Kessels, Wim Stegeman, Walter Scheepmaker, Bastiaan Nuijen, Cynthia Nijenhuis, Melanie Lindenberg, Troels Holz Borch, Tine Monberg, Marco Donia, Inge Marie Svane, Wim van Harten, John B A G Haanen, Valesca P Retel
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial. Journal for immunotherapy of cancer 12 (3) (2024)
Víctor Albarrán Fernández, Pablo Ballestín Martínez, Joachim Stoltenborg Granhøj, Troels Holz Borch, Marco Donia, Inge Marie Svane
Biomarkers for response to TIL therapy: a comprehensive review. Journal for immunotherapy of cancer 12 (3) (2024)
Renske M T Ten Ham, Maartje W Rohaan, Inge Jedema, Rob Kessels, Wim Stegeman, Walter Scheepmaker, Bastiaan Nuijen, Cynthia Nijenhuis, Melanie Lindenberg, Troels Holz Borch, Tine Monberg, Marco Donia, Inge Marie Svane, Wim van Harten, John B A G Haanen, Valesca P Retel
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial. Journal for immunotherapy of cancer 12 (3) (2024)
Renske M T Ten Ham, Maartje W Rohaan, Inge Jedema, Rob Kessels, Wim Stegeman, Walter Scheepmaker, Bastiaan Nuijen, Cynthia Nijenhuis, Melanie Lindenberg, Troels Holz Borch, Tine Monberg, Marco Donia, Inge Marie Svane, Wim van Harten, John B A G Haanen, Valesca P Retel
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial. Journal for immunotherapy of cancer 12 (3) (2024)
Víctor Albarrán Fernández, Pablo Ballestín Martínez, Joachim Stoltenborg Granhøj, Troels Holz Borch, Marco Donia, Inge Marie Svane
Biomarkers for response to TIL therapy: a comprehensive review. Journal for immunotherapy of cancer 12 (3) (2024)
Tine Juul Monberg, Troels Holz Borch, Inge Marie Svane, Marco Donia
TIL Therapy: Facts and Hopes. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Troels Holz Borch, Katja Harbst, Aynal Haque Rana, Rikke Andersen, Evelina Martinenaite, Per Kongsted, Magnus Pedersen, Morten Nielsen, Julie Westerlin Kjeldsen, Anders Handrup Kverneland, Martin Lauss, Lisbet Rosenkrantz Hölmich, Helle Hendel, Özcan Met, Göran Jönsson, Marco Donia, Inge Marie Svane
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma. Journal for immunotherapy of cancer 9 (7) (2022)
Anders Handrup Kverneland, Christopher Aled Chamberlain, Troels Holz Borch, Morten Nielsen, Sofie Kirial Mørk, Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Lise Pyndt Jørgensen, Lene Buhl Riis, Christina Westmose Yde, Özcan Met, Marco Donia, Inge Marie Svane
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types. Journal for immunotherapy of cancer 9 (10) (2022)
Sonja Holm-Yildiz, Clarissa Crone, Troels Holz Borch, Tina Dysgaard Jeppesen
Metastatic melanoma presenting with subacute sensory neuronopathy. Muscle & nerve 64 (2) (2021)
Troels Holz Borch, Rikke Andersen, Eva Ellebaek, Özcan Met, Marco Donia, Inge Marie Svane
Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma. Journal for immunotherapy of cancer 8 (2) (2021)
Aishwarya Gokuldass, Arianna Draghi, Krisztian Papp, Troels Holz Borch, Morten Nielsen, Marie Christine Wulff Westergaard, Rikke Andersen, Aimilia Schina, Kalijn Fredrike Bol, Christopher Aled Chamberlain, Mario Presti, Özcan Met, Katja Harbst, Martin Lauss, Samuele Soraggi, Istvan Csabai, Zoltán Szállási, Göran Jönsson, Inge Marie Svane, Marco Donia
Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma. Cancers 12 (11) (2020)
Arianna Draghi, Troels Holz Borch, Haja Dominike Radic, Christopher Aled Chamberlain, Aishwarya Gokuldass, Inge Marie Svane, Marco Donia
Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs. International journal of cancer 145 (5) (2019)
Magnus Pedersen, Marie Christine Wulff Westergaard, Katy Milne, Morten Nielsen, Troels Holz Borch, Lars Grønlund Poulsen, Helle Westergren Hendel, Mia Kennedy, Gillian Briggs, Stacey Ledoux, Trine Jakobi Nøttrup, Pernille Andersen, Thomas Hasselager, Özcan Met, Brad H Nelson, Marco Donia, Inge Marie Svane
Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study. Oncoimmunology 7 (12) (2018)

Troels Holz Borch.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Troels Holz Borch